|
TOP
|
|
NOXAFIL(posaconazole) suspension
|
HIGHLIGHTS OF PRESCRIBING INFORMATION |
These highlights do not include all the information needed to use NOXAFIL ORAL SUSPENSION safely and effectively. See full prescribing information for NOXAFIL ORAL SUSPENSION.
NOXAFIL® (Posaconazole) ORAL SUSPENSION 40 mg/mL
Initial U.S. Approval: 2006
|
|
RECENT MAJOR CHANGES
|
|
Contraindications, Hypersensitivity (4.1) |
9/2010 |
|
Contraindications, Use with Simvastatin (4.4) |
9/2010 |
|
Warnings and Precautions, Use with Midazolam (5.4) |
9/2010 |
|
|
INDICATIONS AND USAGE
|
|
NOXAFIL is a triazole antifungal agent indicated for:
-
prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy. (1.1)
-
the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole. (1.2)
|
|
|
|
| |
